Inhibition of Phenylhydrazine-induced Hematotoxicity by Bioconverted Ginsenosides

Aim: To identify the inhibition of Phenylhydrazine (PHZ)-induced hepatotoxicity and anemia by bioconverted ginsenosides. Materials and Methods: We examined the potential benefits of bioconverted ginsenosides on anemia in a phenylhydrazine-induced rat model and described the prolonging effect of erythrocyte life span by focusing on compound K that was confirmed through ex vivo experiments. Results: Hematological analysis demonstrated that all groups treated with bioconverted ginsenosides showed significant recovery results. In the ex vivo experiments, compound K was treated in stored blood, and the erythrocytes half-life was 45 days, 15 days longer than when not treated in blood. In the ICP-OES assay, PHZ-induced erythrocyte hemolysis was significantly inhibited by bioconverted ginsenosides. Conclusion: Based on the present results, it has been demonstrated that bioconverted ginsenoside aids in prolonging the erythrocyte life span and increasing erythrocyte count in vivo. Thus, this material has the potential to develop as a promising drug candidate in the future.